DB:22A

Stock Analysis Report

Executive Summary

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Audentes Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 22A's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.9%

22A

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

149.2%

22A

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 22A exceeded the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: 22A exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

22AIndustryMarket
7 Day-0.9%11.7%9.9%
30 Day0%-5.9%-16.6%
90 Day117.2%-22.6%-24.8%
1 Year149.2%149.2%-7.9%-8.1%-15.0%-17.5%
3 Year266.1%266.1%16.6%15.4%-17.4%-24.5%
5 Yearn/a-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Audentes Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Audentes Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 22A (€53) is trading below our estimate of fair value (€157.85)

Significantly Below Fair Value: 22A is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 22A is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 22A is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 22A's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 22A is overvalued based on its PB Ratio (7.2x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Audentes Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

50.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 22A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 22A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 22A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 22A's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 22A's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 22A is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Audentes Therapeutics performed over the past 5 years?

-45.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 22A is currently unprofitable.

Growing Profit Margin: 22A is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 22A is unprofitable, and losses have increased over the past 5 years at a rate of -45.2% per year.

Accelerating Growth: Unable to compare 22A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 22A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 22A has a negative Return on Equity (-45.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is Audentes Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 22A's short term assets ($356.4M) exceed its short term liabilities ($27.9M).

Long Term Liabilities: 22A's short term assets ($356.4M) exceed its long term liabilities ($30.2M).


Debt to Equity History and Analysis

Debt Level: 22A is debt free.

Reducing Debt: 22A had no debt 5 years ago.


Balance Sheet

Inventory Level: 22A has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 22A's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 22A has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 22A has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -32.8% each year.


Next Steps

Dividend

What is Audentes Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 22A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 22A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 22A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 22A's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 22A's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Matt Patterson (47yo)

7.17s

Tenure

US$780,480

Compensation

Mr. Matthew R. Patterson, also known as Matt, has been the Chairman of Audentes Therapeutics Inc., since November 5, 2018 and has been its Director since November 2012. Mr. Patterson co-founded Audentes Th ...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD780.48K) is below average for companies of similar size in the German market ($USD2.07M).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Matthew Patterson
Co-Founder7.17yrsUS$780.48k0.83% $20.7m
Natalie Holles
President & COO1.67yrsUS$1.22m0.19% $4.7m
Thomas Soloway
Executive VP & CFO4.33yrsUS$525.31k0.40% $9.9m
Andrew Chang
Director of Investor Relationsno datano datano data
Mark Meltz
Senior VP & General Counsel0.83yrno data0.071% $1.8m
Sarah Spencer
Vice President of Corporate Communications0.75yrno datano data
David Nagler
Senior VP of Human Resources & Corporate Affairs4.92yrsno datano data
Mary Newman
Senior Vice President of Regulatory Affairs5.25yrsno data0.0014% $35.6k
Fulvio Mavilio
Senior Vice President of Translational Science0.67yrno datano data
Eric Mosbrooker
Senior VP & Chief Commercial Officer1yrno data0.058% $1.4m

1.7yrs

Average Tenure

52yo

Average Age

Experienced Management: 22A's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Matthew Patterson
Co-Founder7.17yrsUS$780.48k0.83% $20.7m
Louis Lange
Lead Independent Director1.17yrsUS$296.54k0.61% $15.2m
Thomas Schuetz
Independent Director6.5yrsUS$298.42k0.19% $4.8m
Scott Morrison
Independent Director4.08yrsUS$305.92kno data
Alan Boyd
Member of Scientific & Clinical Advisory Board3.83yrsno datano data
Julie Smith
Independent Director3.08yrsUS$300.30kno data
Alan Beggs
Member of Scientific & Clinical Advisory Boardno datano datano data
Deborah Bilder
Member of Scientific & Clinical Advisory Board3.83yrsno datano data
Mike Lawlor
Member of Scientific & Clinical Advisory Board3.83yrsno datano data
Benedikt Schoser
Member of Scientific & Clinical Advisory Board3.83yrsno datano data

3.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 22A's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.9%.


Top Shareholders

Company Information

Audentes Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Audentes Therapeutics, Inc.
  • Ticker: 22A
  • Exchange: DB
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.775b
  • Listing Market Cap: US$2.487b
  • Shares outstanding: 46.27m
  • Website: https://www.audentestx.com

Number of Employees


Location

  • Audentes Therapeutics, Inc.
  • 600 California Street
  • 17th Floor
  • San Francisco
  • California
  • 94108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOLDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2016
22ADB (Deutsche Boerse AG)YesCommon StockDEEURJul 2016

Biography

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/15 21:52
End of Day Share Price2020/01/15 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.